WALTHAM, Mass. –  Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced that it intends to offer $200 million of senior subordinated notes due 2016 in a public offering. Payment of the notes will be guaranteed by certain of Inverness' domestic subsidiaries. Inverness intends to use the net proceeds from the offering primarily for general corporate purposes.

UBS Investment Bank, Goldman, Sachs & Co. and Banc of America Securities LLC will act as joint book-running managers for the offering. Canaccord Adams, Leerink Swann and Stifel Nicolaus will serve as co-managers.

The offering will be made under Inverness' shelf registration statement on Form S-3 filed with the SEC on April 10, 2009. Inverness intends to file with the SEC later today a preliminary prospectus supplement and accompanying prospectus for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement, the accompanying prospectus, and the other documents we have filed with the SEC for more complete information about us and the offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a copy of the preliminary prospectus supplement and accompanying prospectus may be obtained from UBS Securities LLC at 677 Washington Boulevard, Stamford, CT 06901, Attention: High Yield Syndicate or at 1-203-719-7991, from Goldman, Sachs & Co. at 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, or at 1-866-471-2526, or Banc of America Securities LLC, at 100 West 33rd Street, 3rd Floor, New York, NY 10001, Attention: Prospectus Department, or at 1-800-294-1322.